Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amivantamab + lazertinib versus osimertinib versus lazertinib in first-line EGFR-mutated advanced or metastatic non-small cell lung cancer
2023-506576-27-00Phase 3Authorised
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2020
- Modality
- Small Molecules, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 27
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Amivantamab + lazertinib, Osimertinib and Lazertinib (3 arms). Primary endpoint: Progression-free survival. Planned start Sep 2020; status: authorised.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2023-506576-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506576-27-00.